Igg Next Generation News Today

EQS-News: Biotest AG / Key word: 9 Month figures Biotest increases EBIT to Euro 125.4 million in the first nine months of 2023 02.11.2023 / 08:00 CET/CEST The issuer...

EQS-News: Biotest AG / Key word: Regulatory Approval Biotest AG: Biotest receives approval for innovative immunoglobulin Yimmugo® in the UK 21.09.2023 / 09:00...

EQS-News: Biotest AG / Key word: Regulatory Admission Biotest AG: US Food and Drug Administration FDA accepts marketing authorization application for immunoglobulin...

EQS-News: Biotest AG / Key word: Half Year Report Biotest AG: Biotest increases EBIT to Euro 19.8 million in the first half of 2023 10.08.2023 / 09:00... -Today at 03:01 am- MarketScreener

EQS-News: Biotest AG / Key word(s): Half Year Report Biotest AG: Biotest increases EBIT to Euro 19.8 million in th...

/PRNewswire/ -- DelveInsights Immune Thrombocytopenia Market Insights report includes a comprehensive understanding of current treatment practices, immune...

The overall immune thrombocytopenia market is anticipated to surge owing to the increasing prevalence of the disease along with promising emerging pipeline therapy during the forecasted period

EQS-News: Biotest AG / Key word(s): 9 Month figuresBiotest AG: Biotest reports sales of Euro 361 million in the first nine months of 2022 14.11.2022 / 09:35 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASE  Biotest reports sales of € 361 million in the first nine...

14.11.2022 - EQS-News: Biotest AG / Key word(s): Regulatory Approval Biotest AG: Biotest receives approval for new intravenous immunoglobulin Yimmugo (IgG Next Generation) 14.11.2022 / 09:30 CET/CEST The issuer is solely responsible for the content of this ... Seite 1

DGAP-News: Biotest AG / Key word(s): Half Year Results Biotest AG: Biotest achieves an improved adjusted EBIT by 9.8% of EUR 32.4 mil...